^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:HER2 Positive Breast Cancer
    Drug:Cipterbin (inetetamab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Real-world Study of Inetetamab for First-line Treatment of MBC

    Excerpt:
    ...- Her2-positive invasive breast cancer confirmed by pathological examination met the following conditions: Positive HER2 expression: Immunohistochemical staining (IHC) showed positive HER2 3+ and/or fluorescence in situ hybridization (FISH);...
    Trial ID:
    NCT05980208
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer

    Excerpt:
    ...Patients with locally recurrent inoperable or metastatic HER2-positive breast cancer: 1....
    Trial ID:
    NCT05291910
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    RWS of Inetetamab HER2 Positive Advanced Breast Cancer

    Excerpt:
    ...Patients with HER2 positive status 3....
    Trial ID:
    NCT04963608
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer

    Excerpt:
    ...Hormone receptor (HR) positive (defined as >1% nuclear estrogen receptor staining); HER2 positive (defined as IHC 3+, or HER2 FISH detection amplification); 12....
    Trial ID:
    Increase
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A real-world study of Inetetamab in the treatment of advanced HER-2 positive breast cancer

    Excerpt:
    ...Subjects with unresectable or recurrent/metastatic HER-2 positive breast cancer confirmed by histology or pathology (no limit on the number of treatment lines); 5. ...
    Trial ID:
    ChiCTR2200061413
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Breast
    Title:

    Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody

    Published date:
    11/01/2023
    Excerpt:
    Cox multivariate analysis revealed that PFS was associated with liver metastasis (hazard ratio [HR] 2.112, 95 % confidence interval [CI] 1.334-3.343, p = 0.001), previous HER2-TKI treatment (HR 2.019, 95 % CI 1.133-3.597, p = 0.017) and estrogen receptor positivity (HR 0.587, 95 % CI 0.370-0.934, p = 0.024).... Inetetamab demonstrates effectiveness with a manageable safety profile, offering a promising therapeutic option for HER2-positive breast cancer patients who have shown resistance to prior anti-HER2 treatments.
    DOI:
    10.1016/j.breast.2023.103597